《美股業績》默沙東(MRK.US)季度多賺57% 料新冠藥全年銷售最多55億美元
道指成分股,美國默沙東藥廠(Merck)(MRK.US)公布首季業績,季度純利43.1億美元,按年升57%,每股季度攤薄純利1.7美元,經調整後為2.14美元。季度銷售159.01億美元,按年升50%,高於市場預期的147億美元。
公司季內大部分銷售增長來自新冠口服藥molnupiravir。扣除該藥的季度銷售按年升19%。公司指,該藥至今已付運640萬個療程,約50萬名病人使用,預期molnupiravir全年銷售50億至55億美元,早前預估為50億至60億美元。
抗癌藥Keytruda季度銷售48億美元,按年升23%,高於市場預期的約45億美元,該藥專利於2028年到期。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.